Charles Marques Lourenço
charlesgenetics.bsky.social
Charles Marques Lourenço
@charlesgenetics.bsky.social
Clinical Geneticist
Neurogenetics and Hereditary Metabolic Disorders Specialist
National Center for Rare Diseases - São José do Rio Preto - Brazil
Reposted by Charles Marques Lourenço
📢 Individuals living with a #CHD3 mutation have better social skills than previously thought. 🧬
#Genetics #RareDisease #EJHG

www.nature.com/articles/s41...
Neurobehavioral profile of individuals with pathogenic variants in CHD3 - European Journal of Human Genetics
European Journal of Human Genetics - Neurobehavioral profile of individuals with pathogenic variants in CHD3
www.nature.com
October 22, 2025 at 10:45 AM
Reposted by Charles Marques Lourenço
The planet’s brightness is dimming—changing rainfall, circulation and temperature
The Blue Marble Is Losing Its Glow
The planet’s brightness is dimming—changing rainfall, circulation and temperature
www.scientificamerican.com
October 22, 2025 at 4:47 PM
Reposted by Charles Marques Lourenço
Analyses of U.K. Biobank and clinical cohorts show that rare genetic diseases can be misdiagnosed as common diseases, which may have implications for clinical trials as well as for diagnosis and treatment. Full study results: nej.md/3Jk1MvD

#MedSky #Genetics
October 22, 2025 at 9:10 PM
Reposted by Charles Marques Lourenço
tired: chapter meetings where people read academic papers for CV lines

wired: teach ins where we educate whoever wants to be educated, exchange pre-ai books, and download shit for folks from whatever databases we still have access to
August 24, 2025 at 12:03 AM
Reposted by Charles Marques Lourenço
Great Blue Heron fluffs its feathers and walks along the shoreline of San Francisco Bay, Emeryville, California.

#birds #nature #eastcoastkin
August 24, 2025 at 10:49 PM
Reposted by Charles Marques Lourenço
Why are some ACMG Annual Meeting sessions non-accredited? Accredited sessions meet strict #CME standards. Others, like industry-led talks or emerging tech, don’t qualify but still offer valuable insights. Learn more: tinyurl.com/bdecv9p8 #ACMGMtg26
July 24, 2025 at 4:19 PM
Reposted by Charles Marques Lourenço
Join us Aug. 27, 2025 at 11:00 AM ET on
@medliveofficial.bsky.social to learn from #MetabolicDisorders experts on the latest care standards and treatment innovations for #PKU. Gain insights to support long-term Phe control and patient well-being. Register: bit.ly/44EWhzw #Phenylketonuria #MedEd
August 6, 2025 at 4:45 PM
Reposted by Charles Marques Lourenço
ACMG publishes new Therapeutics Bulletin: “Lenmeldy (atidarsagene autotemcel) for individuals with early metachromatic leukodystrophy (MLD)” in GIM Open, the College’s gold open access journal: bit.ly/3zRe6iI #Therapeutics #metachromaticleukodystrophy #GIMOpen #medicalgenetics
August 21, 2025 at 1:47 PM
Reposted by Charles Marques Lourenço
Now available online the August episode of GenePod! Learn more about how Rhys Dore and his team gathered patients with variants in ELFN1 from around the world bit.ly/4lxRNzH
August 15, 2025 at 8:09 PM
Reposted by Charles Marques Lourenço
Complex genetic landscape of familial #chylomicronaemia syndrome revealed in the UK population, with regional and ethnic variation and nearly half of FCS cases linked to non-LPL genes. bit.ly/3JjesT0 #GIMO #Hypertriglyceridaemia #AutosomalRecessive
August 14, 2025 at 9:11 PM
Reposted by Charles Marques Lourenço
#GeneticWorkforce limitations call for paradigm shifts. “Genetics First,” program empowers non-geneticist physicians to play an active role in the process of genetic consultation and testing. bit.ly/4lEDv0p #GeneticEducation #TestingAccessibility
August 18, 2025 at 8:57 PM
Reposted by Charles Marques Lourenço
Some limitations of #variant #classification and suggestions to move closer to delivering on the promise of #precision #genomic medicine bit.ly/41O5i7l
August 21, 2025 at 10:34 PM
Reposted by Charles Marques Lourenço
Large-scale look at genomic newborn screening in the UK shows: ✅ Automated pipelines + manual review can scale to 100k babies ✅ High specificity (~97%) keeps false positives low ⚠️ Sensitivity (~80%) needs improvement for diverse variants bit.ly/4mOPxW2
August 22, 2025 at 8:48 PM